{
    "clinical_study": {
        "@rank": "364",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04344249"
        },
        "id_info": {
            "org_study_id": "RC20_0150",
            "nct_id": "NCT04344249"
        },
        "brief_title": "Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic",
        "acronym": "IBD-COVID-19",
        "official_title": "Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital",
                "agency_class": "Other"
            }
        },
        "source": "Nantes University Hospital",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Multicenter cohort of patients followed for 6 months during the pandemic in France with\n      biocollection of sera and peripheral blood mononuclear cells"
        },
        "detailed_description": {
            "textblock": "Multicenter cohort of patients followed for 6 months during the pandemic in France with\n      biocollection of sera and peripheral blood mononuclear cellsNo data has been published\n      concerning the incidence and prevalence of SARS-CoV-2 infection in patients with IBD and\n      treated by IV infusion of infliximab or vedolizumab. It seems that biotherapies have a\n      minimal impact on the severity of the viral infection but data are scarce. The objectives of\n      the cohort are to quantify the incidence and the prevalence of SARS-CoV-2 in this population\n      of patients, to determine clinical, demographic and biological factors associated with the\n      risk of infection and the severity of the disease with a Multicenter cohort of patients\n      followed for 6 months during the pandemic in France with biocollection of sera and peripheral\n      blood mononuclear cells."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 15, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 1, 2021"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "study_type": "Observational [Patient Registry]",
        "has_expanded_access": "No",
        "study_design_info": {
            "observational_model": "Cohort",
            "time_perspective": "Prospective"
        },
        "target_duration": "6 Months",
        "primary_outcome": {
            "measure": "IgG and IgM anti SARS-CoV-2",
            "time_frame": "through study completion, an average of 2 year",
            "description": "Impact of antibodies du to immunosuppressive protocol on the risk of viral infection"
        },
        "secondary_outcome": [
            {
                "measure": "Clinical factors and severity of COVID-19 infection",
                "time_frame": "through study completion, an average of 2 year",
                "description": "Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.\nweight (Kg)\nheight (m)\nABO Group ...."
            },
            {
                "measure": "demographic factors and severity of COVID-19 infection",
                "time_frame": "through study completion, an average of 2 year",
                "description": "Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.\nACCOMMODATION\nHOUSING AREA\nnumber of people at home ...."
            },
            {
                "measure": "pharmacologic factors and severity of COVID-19 infection",
                "time_frame": "through study completion, an average of 2 year",
                "description": "Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management."
            }
        ],
        "enrollment": {
            "@type": "Anticipated",
            "#text": "850"
        },
        "condition": [
            "IBD",
            "COVID"
        ],
        "biospec_retention": "Samples With DNA",
        "biospec_descr": {
            "textblock": "Blood"
        },
        "eligibility": {
            "study_pop": {
                "textblock": "all adult patients with Crohn's disease or ulcerative colitis treated by infliximab or\n        vedolizumab"
            },
            "sampling_method": "Non-Probability Sample",
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients (>18 years), know Crohn's disease or ulcerative colitis, treated by\n             infliximab or vedolizumab\n\n        Exclusion Criteria:\n\n          -  not affiliated to a sanitary social insurance"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "100 Years",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Arnaud Bourreille, Pr",
            "phone": "0240083152",
            "phone_ext": "+(33)",
            "email": "arnaud.bourreille@chu-nantes.fr"
        },
        "location": {
            "facility": {
                "name": "Chu Nantes",
                "address": {
                    "city": "Nantes",
                    "country": "France"
                }
            }
        },
        "location_countries": {
            "country": "France"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 8, 2020",
        "study_first_submitted_qc": "April 10, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "last_update_submitted": "April 10, 2020",
        "last_update_submitted_qc": "April 10, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "IBD",
            "Ulcerative colitis",
            "SARS-CoV-2",
            "infliximab",
            "vedolizumab",
            "Crohn's disease"
        ],
        "condition_browse": {
            "mesh_term": "Inflammatory Bowel Diseases"
        },
        "intervention_browse": {
            "mesh_term": [
                "Infliximab",
                "Vedolizumab"
            ]
        }
    }
}